Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lenehan, John
STOP-GAP, NCT02821013: Duration of Anti-PD-1 Therapy in Metastatic Melanoma	Recruiting	3	614	Canada, RoW	Intermittent PD-1 inhibitor therapy, Continuous PD-1 inhibitor therapy	Canadian Cancer Trials Group, Melanoma and Skin Cancer Trials Limited	Unresectable/Metastatic Melanoma	12/27	12/29
NCT06623461: LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma	Not yet recruiting	2	128	NA	Standard of Care Immune Checkpoint Blockade, LND101	Canadian Cancer Trials Group, Canadian Institutes of Health Research (CIHR), Canadian Cancer Society (CCS), The Weston A. Price Foundation	Melanoma	12/28	06/29
MIMic, NCT03772899: Fecal Microbial Transplantation in Combination With Immunotherapy in Melanoma Patients	Active, not recruiting	1	20	Canada	Fecal Microbial Transplantation	Lawson Health Research Institute	Melanoma	09/21	12/24
CHASe-PDAC, NCT06393400: CHemotherapy And Stool Transplant in PDAC	Not yet recruiting	1	20	Canada	Fecal Microbiota Transplantation, PEG3350, Gemcitabine, nab-Paclitaxel	John Lenehan	Unresectable or Metastatic Advanced Pancreatic Ductal Adenocarcinoma	02/28	02/28